These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7569970)

  • 21. Cellular immunity overrules the protective effect of human DAF as demonstrated in an ex vivo heart perfusion model.
    Verbakel CA; Anegon I; Ménoret S; Marquet RL; Ijzermans JN
    Transplant Proc; 2001; 33(1-2):781-2. PubMed ID: 11267068
    [No Abstract]   [Full Text] [Related]  

  • 22. Human decay accelerating factor transgenic pigs for xenotransplantation obtained by sperm-mediated gene transfer.
    Lavitrano M; Stoppacciaro A; Bacci ML; Forni M; Fioretti D; Pucci L; Di Stefano C; Lazzereschi D; Rughetti A; Ceretta S; Zannoni A; Rahimi H; Moioli B; Rossi M; Nuti M; Rossi G; Seren E; Alfani D; Cortesini R; Frati L
    Transplant Proc; 1999; 31(1-2):972-4. PubMed ID: 10083433
    [No Abstract]   [Full Text] [Related]  

  • 23. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection.
    Pavlov V; Raedler H; Yuan S; Leisman S; Kwan WH; Lalli PN; Medof ME; Heeger PS
    J Immunol; 2008 Oct; 181(7):4580-9. PubMed ID: 18802060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic engineering of the donor species to control hyperacute xenograft rejection.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Adv Nephrol Necker Hosp; 1995; 24():331-40. PubMed ID: 7572417
    [No Abstract]   [Full Text] [Related]  

  • 25. Transgenic pigs for xenotransplantation: selection of promoter sequences for reliable transgene expression.
    Aigner B; Klymiuk N; Wolf E
    Curr Opin Organ Transplant; 2010 Apr; 15(2):201-6. PubMed ID: 20061949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anticoagulant effect of antithrombin III on hyperacute xenograft rejection.
    Takeshita K; Arakawa K; Okamoto M; Akioka K; Fujiwara I; Kobayashi K; Imanishi J; Oka T
    Transplant Proc; 1996 Apr; 28(2):631-2. PubMed ID: 8623314
    [No Abstract]   [Full Text] [Related]  

  • 27. Continuous complement (C) inhibition using soluble C receptor type 1 (sCR1): effect on hyperacute rejection (HAR) of pig-to-primate cardiac xenografts.
    Pruitt Sk; Bollinger RR; Collins BH; Marsh HC; Levin JL; Rudolph AR; Baldwin WM; Sanfilippo F
    Transplant Proc; 1996 Apr; 28(2):756. PubMed ID: 8623382
    [No Abstract]   [Full Text] [Related]  

  • 28. Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement pathway-regulatory protein.
    Azimzadeh AM; Kelishadi SS; Ezzelarab MB; Singh AK; Stoddard T; Iwase H; Zhang T; Burdorf L; Sievert E; Avon C; Cheng X; Ayares D; Horvath KA; Corcoran PC; Mohiuddin MM; Barth RN; Cooper DK; Pierson RN
    Xenotransplantation; 2015; 22(4):310-6. PubMed ID: 26174749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential mechanism of abnormal thromboregulation in xenograft rejection: loss of ecto-ATPases upon endothelial cell activation.
    Robson SC; Candinas D; Siegel JB; Kopp C; Millan M; Hancock WW; Bach FH
    Transplant Proc; 1996 Apr; 28(2):536. PubMed ID: 8623252
    [No Abstract]   [Full Text] [Related]  

  • 30. Development and analysis of transgenic pigs expressing the human complement regulatory protein CD59 and DAF.
    Byrne G; McCurry K; Martin M; Platt J; Logan J
    Transplant Proc; 1996 Apr; 28(2):759. PubMed ID: 8623385
    [No Abstract]   [Full Text] [Related]  

  • 31. Delayed xenograft rejection in C3-depleted discordant (pig-to-baboon) cardiac xenografts treated with cobra venom factor.
    Kobayashi T; Taniguchi S; Ye Y; Niekrasz M; Kosanke S; Neethling FA; Wright LJ; Rose AG; White DJ; Cooper DK
    Transplant Proc; 1996 Apr; 28(2):560. PubMed ID: 8623270
    [No Abstract]   [Full Text] [Related]  

  • 32. Progress in transgenic pigs for xenotransplantation.
    Ascher NL
    Liver Transpl Surg; 1998 Mar; 4(2):180-1. PubMed ID: 9516573
    [No Abstract]   [Full Text] [Related]  

  • 33. Xenografts are an achievable breakthrough.
    Alisky JM
    Med Hypotheses; 2004; 63(1):92-7. PubMed ID: 15193356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acid-base and electrolyte disturbances in an experimental model of orthotopic liver xenotransplantation from pig to baboon after graft reperfusion: differences between h-DAF livers and unmodified livers.
    Palenciano CG; Segura B; Ramirez P; Chavez R; Munitiz V; Cayuela MG; Acosta F; Sansano T; Majado M; Muñoz A; Hernandez O; Pino-Chavez G; Loba M; Yelamos J; Gago MR; Vizcaino AS; Asensi H; Marin F; Rubio A; Fuente T; Rios A; Montoya M; Robles R; Bueno FS; Rodriguez JM; Navarro F; Cabezuelo J; Cozzi E; White DJ; Parrilla P
    Transplant Proc; 2002 Feb; 34(1):325-6. PubMed ID: 11959309
    [No Abstract]   [Full Text] [Related]  

  • 35. Specific intravenous carbohydrate therapy: a new approach to the inhibition of antibody-mediated rejection following ABO-incompatible allografting and discordant xenografting.
    Cooper DK; Good AH; Ye Y; Koren E; Oriol R; Ippolito RM; Malcolm AJ; Neethling FA; Romano E; Zuhdi N
    Transplant Proc; 1993 Feb; 25(1 Pt 1):377-8. PubMed ID: 8438342
    [No Abstract]   [Full Text] [Related]  

  • 36. Strong xenoprotective function by single-copy transgenes placed sequentially at a permissive locus.
    Rieblinger B; Fischer K; Kind A; Saller BS; Baars W; Schuster M; Wolf-van Buerck L; Schäffler A; Flisikowska T; Kurome M; Zakhartchenko V; Kessler B; Flisikowski K; Wolf E; Seissler J; Schwinzer R; Schnieke A
    Xenotransplantation; 2018 Mar; 25(2):e12382. PubMed ID: 29359453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of hyperacute rejection in a model of orthotopic liver xenotransplantation from pig to baboon using polytransgenic pig livers (CD55, CD59, and H-transferase).
    Ramírez P; Montoya MJ; Ríos A; García Palenciano C; Majado M; Chávez R; Muñoz A; Fernández OM; Sánchez A; Segura B; Sansano T; Acosta F; Robles R; Sánchez F; Fuente T; Cascales P; González F; Ruiz D; Martínez L; Pons JA; Rodríguez JI; Yélamos J; Cowan P; d'Apice A; Parrilla P
    Transplant Proc; 2005 Nov; 37(9):4103-6. PubMed ID: 16386637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A look at potential ESRD treatment alternatives for the future. Xenotransplantation.
    Williams RD
    Nephrol News Issues; 1997 Aug; 11(8):35-7. PubMed ID: 9335781
    [No Abstract]   [Full Text] [Related]  

  • 39. Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival.
    Stevens RB; Wang YL; Kaji H; Lloveras J; Dalmasso A; Bach FH; Rubinstein P; Sutherland DE; Platt JL
    Transplant Proc; 1993 Feb; 25(1 Pt 1):382. PubMed ID: 8438344
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic engineering of endothelial cells to ameliorate xenograft rejection.
    Bach FH; Robson SC; Wrighton CJ; Stuhlmeier K; Ferran C; Winkler H
    Clin Transplant; 1996 Feb; 10(1 Pt 2):124-7. PubMed ID: 8680048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.